Memantine Hydrochloride Tablet
Product Images NDC 31722-808

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 31722-808). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantinetabs-figure6 (Memantinetabs Figure6)

A cumulative percentage curve comparing patients' ADCS-ADL change from baseline between two groups: Placebo/Donepezil and Memantine Hydrochloride Tablets/Donepezil. The x-axis represents the ADCS-ADL change from baseline, and the y-axis represents the cumulative percentage of patients. Two distinct curves are shown, one for each treatment group.*

FDA Label Image

Memantinetabs10mg60scount (Memantinetabs10mg60scount)

Label for Memantine Hydrochloride Tablets USP, 10 mg, oral tablets, with a package size of 60 tablets. The label shows the NDC 31722-808-60 and indicates it is manufactured for Camber Pharmaceuticals, Inc. The label includes storage instructions, drug contact information, and a barcode. Manufacturer details include Annora Pharma Pvt. Ltd. in Telangana, India.*

FDA Label Image

Memantinetabs5mg60scount (Memantinetabs5mg60scount)

Label for Memantine Hydrochloride Tablets USP 5 mg, oral tablets packaged as 60 tablets per container. The label includes the Camber Pharmaceuticals, Inc. logo, dosage strength highlighted in yellow, NDC number 31722-807-60, barcode, manufacturing and contact information, and storage instructions. The label also includes a pink area designated for batch coding.*

FDA Label Image

Memantinetabscamberlogo (Memantinetabscamberlogo)

FDA Label Image

Memantinetabsfigure1 (Memantinetabsfigure1)

A line graph depicting the mean change from baseline in ADCS-ADL scores over 28 weeks of treatment, comparing memantine hydrochloride tablets and placebo. The graph shows clinical improvement and decline markers, with memantine hydrochloride maintaining scores closer to baseline compared to placebo.*

FDA Label Image

Memantinetabsfigure2 (Memantinetabsfigure2)

A cumulative percentage chart depicting patient response differences among Placebo, Memantine Hydrochloride, and Tablets groups. The x-axis shows ADCS-ADL change from baseline with negative values, while the y-axis shows the cumulative percentage of patients from 0 to 100%. The graph compares outcomes across these groups using distinct markers.*

FDA Label Image

Memantinetabsfigure3 (Memantinetabsfigure3)

A line graph showing the mean change from baseline in SIB score over 28 weeks of treatment comparing memantine hydrochloride tablets and placebo. The y-axis represents the mean change with SEM, ranging from clinical improvement to clinical decline, while the x-axis indicates weeks of treatment. The memantine group shows stable or slight improvement, whereas the placebo group shows a decline over time.*

FDA Label Image

Memantinetabsfigure4 (Memantinetabsfigure4)

A cumulative percentage curve chart depicting the percentage of patients versus SIB change from baseline over 28 weeks of treatment for memantine hydrochloride tablets compared to placebo. The graph shows two plotted lines representing both groups across the study duration.*

FDA Label Image

Memantinetabsfigure5 (Memantinetabsfigure5)

This line graph depicts the mean change from baseline in ADCS-ADL scores over 24 weeks of treatment comparing Memantine Hydrochloride Tablets/Donepezil and Placebo/Donepezil groups. The x-axis represents weeks of treatment, and the y-axis shows mean change indicating clinical improvement or decline. Error bars indicate the standard error of the mean (SEM).*

FDA Label Image

Memantinetabsfigure7 (Memantinetabsfigure7)

A line graph depicting mean change from baseline in SIB score over 24 weeks of treatment. The graph compares two groups: placebo/donepezil (black squares) and memantine hydrochloride tablets/donepezil (white circles). The y-axis measures mean change with error bars, highlighting clinical improvement above the baseline and clinical decline below it. The memantine group shows an increase peaking around 12 weeks, while the placebo group remains near baseline or declines.*

FDA Label Image

Memantinetabsfigure8 (Memantinetabsfigure8)

A cumulative distribution plot showing the percentage of patients on the y-axis against SIB change from baseline on the x-axis for memantine hydrochloride tablets combined with donepezil compared to placebo with donepezil. The graph contrasts treatment effects on cognitive function changes.*

FDA Label Image

Memantinetabsstructure (Memantinetabsstructure)

Chemical structure diagram of memantine hydrochloride, showing the molecular arrangement including an amine group and hydrochloride component, consistent with the active ingredient memantine hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.